Conjoint Analysis and Biologic Decision-Making

The IBD patient conjoint survey included the biologic attributes shown in the Table.

Biologic AttributeAttribute Levels
Mechanism of action
  • Blocks a signal in the immune system that causes inflammation in the GI tract and other parts of the body
  • Blocks the movement of gut-directed immune cells into the GI tract, which helps to control inflammation
Route and frequency of administration
  • Given through an IV into the vein over 30 minutes at a clinic every 8 weeks
  • Given through an IV into the vein over 2 hours at a clinic every 8 weeks
  • Injected under the skin every two weeks at your home
  • Injected under the skin every four weeks at your home
Short-term improvement (i.e., chance symptoms will improve within 2 months
  • 30%
  • 40%
  • 50%
  • 60%
Long-term remission (i.e., chance of being symptom-free in 1 year)
  • 10%
  • 20%
  • 30%
  • 40%
Tolerability of unwanted side effects (i.e., chance of stopping the medicine because of side effects)
  • 1%
  • 5%
  • 10%
  • 15%
Risk of fatigue
  • 1%
  • 5%
  • 10%
Risk of rash
  • 1%
  • 5%
  • 10%
  • 15%
Risk of serious infection
  • 25 out of 1,000
  • 30 out of 1,000
  • 35 out of 1,000
  • 40 out of 1,000
Risk of lymphoma
  • 3 out of 10,000
  • 5 out of 10,000
  • 7 out of 10,000
  • 9 out of 10,000
aa
<<12>>